Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Long-term outcome of patients with p22phox-deficient chronic granulomatous disease on Jeju Island, Korea

  • Kang, Hyun Sik (Department of Pediatrics, Jeju National University School of Medicine) ;
  • Hwang, Geol (Department of Pediatrics, Jeju National University School of Medicine) ;
  • Shin, Kyung-Sue (Department of Pediatrics, Jeju National University School of Medicine)
  • 투고 : 2014.05.23
  • 심사 : 2014.09.25
  • 발행 : 2015.04.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: This study investigated the long-term clinical outcomes of patients with $p22^{phox}$-deficient chronic granulomatous disease (CGD) on Jeju Island and retrospectively evaluated the effects of interferon-gamma (IFN-${\gamma}$) prophylaxis. Methods: The medical records of 15 patients with CGD were retrospectively reviewed. The efficacy of IFN-${\gamma}$ prophylaxis was evaluated by comparing the frequency of severe infections before and after starting continuous prophylaxis with IFN-${\gamma}$. Results: At the time of the analysis, 14 patients were alive, with a median age of 14.3 years. The diagnosis of CGD was made at a median age of 2.4 years, and the median age at onset of severe infection was 0.3 years. Thirteen of the 15 patients had their first severe infection within the first year of life. The overall incidence of severe infection was 1.36 infections per patient-year; pneumonia, suppurative lymphadenitis, and skin and subcutaneous abscesses were the most common infections. Aspergillus species were the most frequently isolated microorganisms, present in 15.8% of isolates. IFN-${\gamma}$ did not significantly change the rate of severe infection. The survival rate for patients after 2 years of age was 93%; there was a prolonged survival plateau beyond the age of 2. Conclusion: Compared with cases of X-linked CGD reported in other studies, patients with CGD on Jeju Island did not show obviously different clinical manifestations, but they had a significantly higher survival rate. Further studies with a substantially longer period of observation, and with more patients under intensive surveillance are necessary to elucidate the prophylactic efficiency of IFN-${\gamma}$.

키워드

참고문헌

  1. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-69. https://doi.org/10.1097/00005792-200005000-00003
  2. Kuijpers T, Lutter R. Inflammation and repeated infections in CGD: two sides of a coin. Cell Mol Life Sci 2012;69:7-15. https://doi.org/10.1007/s00018-011-0834-z
  3. Segal BH, Veys P, Malech H, Cowan MJ. Chronic granulomatous disease: lessons from a rare disorder. Biol Blood Marrow Transplant 2011;17(1 Suppl):S123-31. https://doi.org/10.1016/j.bbmt.2010.09.008
  4. Holland SM. Chronic granulomatous disease. Hematol Oncol Clin North Am 2013;27:89-99. https://doi.org/10.1016/j.hoc.2012.11.002
  5. Stasia MJ, Li XJ. Genetics and immunopathology of chronic granulomatous disease. Semin Immunopathol 2008;30:209-35. https://doi.org/10.1007/s00281-008-0121-8
  6. Roos D, Kuhns DB, Maddalena A, Roesler J, Lopez JA, Ariga T, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 2010;45:246-65. https://doi.org/10.1016/j.bcmd.2010.07.012
  7. Roos D, Kuhns DB, Maddalena A, Bustamante J, Kannengiesser C, de Boer M, et al. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol Dis 2010;44:291-9. https://doi.org/10.1016/j.bcmd.2010.01.009
  8. Matute JD, Arias AA, Wright NA, Wrobel I, Waterhouse CC, Li XJ, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009;114:3309-15. https://doi.org/10.1182/blood-2009-07-231498
  9. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS One 2009;4:e5234. https://doi.org/10.1371/journal.pone.0005234
  10. Rhim JW, Kim KH, Kim DS, Kim BS, Kim JS, Kim CH, et al. Prevalence of primary immunodeficiency in Korea. J Korean Med Sci 2012;27:788-93. https://doi.org/10.3346/jkms.2012.27.7.788
  11. Kim YM, Park JE, Kim JY, Lim HK, Nam JK, Cho M, et al. Genetic analysis of 10 unrelated Korean families with p22-phox-deficient chronic granulomatous disease: an unusually identical mutation of the CYBA gene on Jeju Island, Korea. J Korean Med Sci 2009;24:1045-50. https://doi.org/10.3346/jkms.2009.24.6.1045
  12. Cho M, Shin KS. Chronic granulomatous disease on Jeju Island, Korea. J Genet Med 2013;10:1-6. https://doi.org/10.5734/JGM.2013.10.1.1
  13. Wolach B, Gavrieli R, de Boer M, Gottesman G, Ben-Ari J, Rottem M, et al. Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients. Clin Immunol 2008;129:103-14. https://doi.org/10.1016/j.clim.2008.06.012
  14. Teimourian S, Zomorodian E, Badalzadeh M, Pouya A, Kannengiesser C, Mansouri D, et al. Characterization of six novel mutations in CYBA: the gene causing autosomal recessive chronic granulomatous disease. Br J Haematol 2008;141:848-51. https://doi.org/10.1111/j.1365-2141.2008.07148.x
  15. Kim JG, Shin KS, Park JS. Clinical study on chronic granulomatous disease in Korea. Korean J Immunol 1999;21:271-83.
  16. Liese J, Kloos S, Jendrossek V, Petropoulou T, Wintergerst U, Notheis G, et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr 2000;137:687-93. https://doi.org/10.1067/mpd.2000.109112
  17. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol 2008;126:155-64. https://doi.org/10.1016/j.clim.2007.09.008
  18. Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010;363:2600-10. https://doi.org/10.1056/NEJMoa1007097
  19. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991;324:509-16. https://doi.org/10.1056/NEJM199102213240801
  20. Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 2004;39:692-9. https://doi.org/10.1086/422993
  21. Guide SV, Stock F, Gill VJ, Anderson VL, Malech HL, Gallin JI, et al. Reinfection, rather than persistent infection, in patients with chronic granulomatous disease. J Infect Dis 2003;187:845-53. https://doi.org/10.1086/368388

피인용 문헌

  1. Mastoidectomy in a child with chronic granulomatous disease vol.78, pp.10, 2015, https://doi.org/10.12968/hmed.2017.78.10.586